| scholarly article | Q13442814 |
| P50 | author | Ferdows Atiq | Q85371270 |
| Karin P M van Galen | Q88692405 | ||
| Jeroen C J Eikenboom | Q42337451 | ||
| P2093 | author name string | Johanna G van der Bom | |
| Paula F Ypma | |||
| Karin Fijnvandraat | |||
| Frank W G Leebeek | |||
| Marjon H Cnossen | |||
| Karina Meijer | |||
| Britta A P Laros-van Gorkom | |||
| Eveline P Mauser-Bunschoten | |||
| Joke de Meris | |||
| WiN study group | |||
| Moniek P de Maat | |||
| Marten R Nijziel | |||
| P2860 | cites work | von Willebrand disease: clinical and laboratory lessons learned from the large von Willebrand disease studies | Q26863636 |
| Impact, diagnosis and treatment of von Willebrand disease | Q74225973 | ||
| Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy | Q74764842 | ||
| Von Willebrand factor in diabetic angiopathy | Q77523254 | ||
| Von Willebrand factor in Italian centenarians | Q78846136 | ||
| Reassessment of ABO blood group, sex, and age on laboratory parameters used to diagnose von Willebrand disorder: potential influence on the diagnosis vs the potential association with risk of thrombosis | Q82279339 | ||
| Variation in the von Willebrand factor gene is associated with von Willebrand factor levels and with the risk for cardiovascular disease | Q85184060 | ||
| LDL receptor-related protein-1: a regulator of inflammation in atherosclerosis, cancer, and injury to the nervous system | Q30408735 | ||
| Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor | Q33998293 | ||
| The effect of ABO blood group on the diagnosis of von Willebrand disease. | Q34180946 | ||
| Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension | Q36015782 | ||
| Changes in von Willebrand factor level and von Willebrand activity with age in type 1 von Willebrand disease | Q36369902 | ||
| ABO blood group determines plasma von Willebrand factor levels: a biologic function after all? | Q36604393 | ||
| Bleeding scores in inherited bleeding disorders: clinical or research tools? | Q37064511 | ||
| When von Willebrand disease comes into age - a matter of change? | Q37854842 | ||
| von Willebrand factor and cancer: a renewed interest | Q38080207 | ||
| von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends | Q38364984 | ||
| Platelet-dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH. | Q38413638 | ||
| Update of thrombosis in multiple myeloma | Q38805434 | ||
| Temporary relief of symptomatic Von Willebrand disease by multiple myeloma | Q39367487 | ||
| von Willebrand factor and inflammation | Q39410942 | ||
| von Willebrand factor fibers promote cancer-associated platelet aggregation in malignant melanoma of mice and humans | Q40671371 | ||
| VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease | Q42937413 | ||
| Increase of von Willebrand factor with aging in type 1 von Willebrand disease: fact or fiction? | Q44385751 | ||
| Generation and validation of the Condensed MCMDM-1VWD Bleeding Questionnaire for von Willebrand disease | Q45145414 | ||
| Acquired von Willebrand syndrome in patients with overt hypothyroidism: a prospective cohort study. | Q45857162 | ||
| von Willebrand factor propeptide and the phenotypic classification of von Willebrand disease | Q45872935 | ||
| Plasma von Willebrand factor and arterial aging | Q46447114 | ||
| Angiotensin II upregulates LDL receptor-related protein (LRP1) expression in the vascular wall: a new pro-atherogenic mechanism of hypertension | Q46748422 | ||
| Outgrowing the laboratory diagnosis of type 1 von Willebrand disease: A two decade study. | Q47664550 | ||
| Health-related quality of life among adult patients with moderate and severe von Willebrand disease | Q48852651 | ||
| Von Willebrand's Disease. | Q51270177 | ||
| Biological Variation of Hemostasis Variables in Thrombosis and Bleeding: Consequences for Performance Specifications. | Q51454225 | ||
| Increased plasma levels of endothelin 1 and von Willebrand factor in patients with type 2 diabetes and dyslipidemia. | Q54037730 | ||
| Prothrombotic coagulation abnormalities in patients with newly diagnosed multiple myeloma. | Q54220038 | ||
| Aging and ABO blood type influence von Willebrand factor and factor VIII levels through interrelated mechanisms. | Q55283293 | ||
| A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD) | Q59511676 | ||
| Relation of the Prothrombotic State to Increasing Age (from the Framingham Offspring Study) | Q59608032 | ||
| CLEC4MandSTXBP5gene variations contribute to von Willebrand factor level variation in von Willebrand disease | Q62107228 | ||
| von Willebrand disease and aging: an evolving phenotype | Q62107242 | ||
| Reduced prevalence of arterial thrombosis in von Willebrand disease | Q62107281 | ||
| Determinants of bleeding phenotype in adult patients with moderate or severe von Willebrand disease | Q62107310 | ||
| Alterations in C1 inhibitor and clotting factor concentrations in primary biliary cirrhosis and other chronic liver diseases | Q68712212 | ||
| Hypothyroidism as a cause of acquired von Willebrand's disease | Q69898280 | ||
| Factor VIII activity in normal volunteers receiving oral thyroid hormone | Q70445524 | ||
| Admission criteria for immunogerontological studies in man: the SENIEUR protocol | Q70719192 | ||
| Correlation between oxidized low density lipoproteins and von Willebrand factor in chronic renal failure | Q71848950 | ||
| Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study | Q72653454 | ||
| Elevated plasma levels of VWF:Ag in hyperthyroidism are mediated through beta-adrenergic receptors | Q72723262 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | comorbidity | Q1414874 |
| P304 | page(s) | 93-105 | |
| P577 | publication date | 2018-05-16 | |
| P1433 | published in | British Journal of Haematology | Q4970200 |
| P1476 | title | Comorbidities associated with higher von Willebrand factor (VWF) levels may explain the age-related increase of VWF in von Willebrand disease | |
| P478 | volume | 182 |
| Q91630620 | BMI is an important determinant of VWF and FVIII levels and bleeding phenotype in patients with von Willebrand disease |
| Q97551370 | Low VWF: insights into pathogenesis, diagnosis, and clinical management |
| Q90307753 | One piece of the puzzle: Population pharmacokinetics of FVIII during perioperative Haemate P® /Humate P® treatment in von Willebrand disease patients |
| Q91959533 | von Willebrand factor and factor VIII levels after desmopressin are associated with bleeding phenotype in type 1 VWD |
Search more.